Clinical reference Biomarker Directory
Back to directory

EPO

Established

EPO is a kidney hormone used to distinguish causes of abnormal red blood cell counts and guide CKD anemia treatment.

Also known as Erythropoietin EPO hormone
In plain language

EPO is a kidney hormone that tells the body to make more red blood cells. Measuring it helps distinguish different causes of abnormal blood counts, and it's also the basis for anemia treatment in kidney disease — plus a well-known target of blood doping in sports.

Biomarker & context

Erythropoietin (EPO) is a hormone produced mainly by the kidneys that stimulates red blood cell production in the bone marrow in response to low oxygen levels.

What it indicates

EPO levels help distinguish causes of abnormal red blood cell counts: low EPO with elevated hemoglobin points toward polycythemia vera (a bone marrow disorder), while inappropriately low EPO relative to the degree of anemia is characteristic of anemia of chronic kidney disease.

Diagnosis & clinical testing

Measured via serum immunoassay; in CKD, the kidneys fail to produce adequate EPO for the degree of anemia present, which is the rationale for treating these patients with erythropoiesis-stimulating agents (ESAs) rather than iron alone.

Guiding treatment

ESA therapy is guided by EPO physiology in CKD-related anemia, though dosing requires careful monitoring given cardiovascular risk with aggressive correction; EPO is also a World Anti-Doping Agency-controlled substance due to its blood-doping potential in competitive sports.

Clinical significance

Also a well-known blood-doping target, subject to anti-doping regulation in competitive sports.

References
  1. General nephrology and hematology reference literature on erythropoietin physiology in CKD-associated anemia and polycythemia vera diagnosis.